Cost of translating consent documents may serve as a barrier to participation of members of underrepresented groups in clinical trials

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.

January 31, 2025

Drugs & Targets

Yunu, WCG collaborate to support clinical trial imaging services

Yunu and WCG announced a partnership in support of WCG’s imaging services.

January 31, 2025

Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.

January 24, 2025

Vol.51 No.03

In Brief

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

In Brief

Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania

A recent report showed that UPMC Hillman Cancer Center generated $3.98 billion in total economic impact in Pennsylvania through its clinical, research, and educational missions in 2023.

January 17, 2025

Vol.51 No.02

Cost of translating consent documents may serve as a barrier to participation of members of underrepresented groups in clinical trials

YOU MAY BE INTERESTED IN

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

Yunu, WCG collaborate to support clinical trial imaging services

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

David Chung named director of clinical research at Northwell Health

Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania

Renew today!

Subscriber content

Never miss an issue!

Login